Sesen Bio, Inc. (NASDAQ:SESN) is reporting third quarter earnings results on Monday 9th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.08 per share.
For the full year, analysts predict loss of $ 0.05 per share.
Stock Performance
On Friday, shares of Sesen Bio, Inc. has traded high as $ 1.06 and has cracked $ 1.01 on the downward trend, reaching $ 1.03 with volume of 914.30 thousand shares.
According to the previous trading day, closing price of $ 1.03, representing a 186.49 % increase from the 52 week low of $ 0.37 and a 31.17 % decrease over the 52 week high of $ 1.54.
The company has a market capital of $ 132.84 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Sesen Bio, Inc. will be hosting a conference call at 8:00 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sesenbio.com
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The companys lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZenecas checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck.
